$PHIO

Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_965504.htm EXHIBIT 99.1 ex_965504.htm Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical to

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. phio20260717_8k.htm false 0001533040 0001533040 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event repo

Phio Pharmaceuticals (PHIO) said it received multiple favorable patent actions for its INTASYL gene-silencing platform, including three Notices of Allowance and one patent grant in the US, Canada, and Japan. The company said the expanded IP protection supports R&D, partnerships, and commercialization. Phio’s INTASYL portfolio totals 54 issued patents. Shares were up 4.01% at $1.04.

Phio Pharmaceuticals (NASDAQ: PHIO) said it received multiple favorable patent actions, including three notices of allowance and one grant decision, to strengthen its INTASYL siRNA intellectual property in the US, Canada, and Japan. The company said its portfolio includes 54 issued patents covering INTASYL chemistry, targets, and immuno-oncology indications.

Bitterman Robert J (Chairman, Pres. & CEO) purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $0.99 on 2026-06-26.

Phio Pharmaceuticals (NASDAQ: PHIO) shares surged after the company announced positive Phase 1b clinical trial results for its lead candidate, PH-762. The trial for skin cancer patients showed an 85% pathological response rate and complete tumor clearance in a significant number of patients at the highest dose. The company plans an FDA submission in Q2 2026 to discuss future clinical study design.

Shares of Phio Pharmaceuticals Corp. ( NASDAQ:PHIO ) are rising Monday after the company provided an update on an ongoing medical trial. PHIO is charging ahead with explosive momentum. Track the action here.

Phio Pharmaceuticals ( NASDAQ:PHIO ) , a biotechnology company developing gene-silencing therapies for cancer, released its second quarter 2025 results on August 14, 2025. The quarter's key news included a GAAP EPS of $ ( 0.45 ) , missing the consensus GAAP estimate of $ ( 0.36 ) by $0.09.

PHIO, ALRS and URBN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 28, 2025.